Loading…
Quest Diagnostics Incorporated is projected to rise to $269.87 by 2027, a +30% move from its current price of $207.44. DGX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $205.20 | $207.51 | $209.85 | +0.03% |
| Jul 14 | $204.32 | $207.58 | $210.90 | +0.07% |
| Jul 15 | $203.66 | $207.65 | $211.72 | +0.10% |
| Jul 16 | $203.12 | $207.72 | $212.43 | +0.14% |
| Jul 17 | $202.65 | $207.80 | $213.07 | +0.17% |
| Jul 18 | $202.24 | $207.87 | $213.65 | +0.21% |
| Jul 19 | $201.86 | $207.94 | $214.19 | +0.24% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $201.86 | $207.94 | $214.19 | +0.24% |
| Week 2 | $199.88 | $208.44 | $217.36 | +0.48% |
| Week 3 | $198.48 | $208.94 | $219.95 | +0.72% |
| Week 4 | $197.38 | $209.44 | $222.23 | +0.96% |
| Week 5 | $196.47 | $209.94 | $224.33 | +1.20% |
| Week 6 | $195.70 | $210.44 | $226.29 | +1.45% |
| Week 7 | $195.03 | $210.95 | $228.16 | +1.69% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States, developing and delivering diagnostic information services such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It operates under the Quest Diagnostics brand, as well as AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. It also offers risk assessment services for the life insurance industry and healthcare IT health providers and payers, test offerings across cardiometabolic and endocrine, cancer, clinical drug monitoring and toxicology, infectious disease including autoimmune, neurology diagnostics including Alzheimer's disease, and women’s health such as prenatal genetic testing, workplace drug testing, and employer population health services.
Further, it provides population health solutions, extended care services, develops in vitro diagnostic tests, laboratory diagnostic information and digital health connectivity systems, underwriting support services, data gathering and analytics, and national specimen collection and health data solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
DGX is Quest Diagnostics Incorporated, a healthcare stock focused on diagnostic testing and related information services. Current price: $209.88 per share, with a market cap of $23.23B and a rank of 545. The stock sits in a near-term price framework that combines technical momentum with clearly defined support and resistance levels.
In recent action, the 30-day technical picture shows bullish sentiment with an RSI reading of 70 and short- to mid-term moving averages around the current price. The market’s volatility is captured by an annualized volatility of 20%.
A major floor 12.6% below — a decisive break under it would weaken the trend.
The nearest floor, 7.3% below — buyers have tended to step in here.
The nearest ceiling, 4.1% above — a clean break opens room to run.
A major ceiling 10.4% above — clearing it would confirm fresh momentum.
Key DGX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of DGX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $209.91 | Sell | $209.26 | Sell |
| MA 10 | $211.57 | Sell | $209.12 | Sell |
| MA 20 | $205.94 | Buy | $206.54 | Buy |
| MA 50 | $198.24 | Buy | $201.54 | Buy |
| MA 100 | $199.03 | Buy | $197.74 | Buy |
| MA 200 | $191.41 | Buy | $191.85 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 54.56 | Neutral |
| Stoch RSI (14) | 38.90 | Neutral |
| CCI (20) | 17.69 | Neutral |
| Williams %R (14) | -38.24 | Info |
| MACD (12,26,9) | -0.27 | Sell |
| ROC (12) | 5.20 | Buy |
| Bollinger %B (20,2) | 0.56 | Neutral |
| Stochastic %K (14) | 61.76 | Neutral |
| TRIX (15) | 0.28 | Buy |
| Awesome (5,34) | 7.94 | Buy |
| Ultimate (7,14,28) | 46.45 | Neutral |
| Momentum (10) | 1.20 | Buy |
| Aroon Osc (25) | 28.00 | Buy |
| Hull MA (9) | 207.16 | Buy |
| ADX (14) | 20.40 | Buy |
| ATR (14) | 2.14 | Info |
The near-term setup remains bullish, with sentiment labeled BULLISH and an RSI of 70. The stock trades with a nearby resistance at $209.88 and a support at $186.61, offering a structured path within a defined trading range.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $173.49 | $207.44 | $274.31 | 0% | Neutral | |
| $221.03 | $269.87 | $344.50 | +30% | Bullish | |
| $250.39 | $311.46 | $408.34 | +50% | Bullish | |
| $286.11 | $361.39 | $483.90 | +74% | Bullish | |
| $309.79 | $396.59 | $540.59 | +91% | Bullish | |
| $313.54 | $406.29 | $562.57 | +96% | Bullish | |
| $342.31 | $448.59 | $629.97 | +116% | Bullish | |
| $364.51 | $482.71 | $686.67 | +133% | Bullish | |
| $421.79 | $564.12 | $812.07 | +172% | Bullish | |
| $500.02 | $675.07 | $982.60 | +225% | Bullish | |
| $619.45 | $872.27 | $1,330.53 | +320% | Bullish | |
| $1,231.26 | $1,859.48 | $3,040.38 | +796% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $173.49 | $207.44 | $245.04 | +0.00% |
| August 2026 | $181.53 | $212.48 | $254.09 | +2.43% |
| September 2026 | $181.96 | $214.01 | $257.92 | +0.72% |
| October 2026 | $179.46 | $211.94 | $257.11 | -0.97% |
| November 2026 | $182.83 | $216.67 | $264.29 | +2.23% |
| December 2026 | $188.18 | $223.73 | $274.31 | +3.26% |
Click any year to see its month-by-month DGX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The DGX price prediction for 2026 points to an average of $207.44 (low $173.49, high $274.31) — a potential gain of 0% on today's $207.44. Price action looks broadly range-bound.
In 2027, DGX is projected to trade between $221.03 and $344.50, averaging $269.87 — a potential gain of +30% from today's $207.44. That is up +30% on the projected 2026 average. Buyers look set to stay in control over this stretch.
Quest Diagnostics Incorporated's 2028 outlook centres on $311.46, within a $250.39 to $408.34 range. That is up +15% on the projected 2027 average. That marks a +50% change versus current levels. Momentum favours further upside here.
By 2029, DGX could reach as high as $483.90, with a base case around $361.39 and support toward $286.11 — roughly +74% from $207.44. Buyers look set to stay in control over this stretch.
Expect DGX to range from $309.79 to $540.59 through 2030. The $396.59 average target implies a +91% move from current prices. That is up +10% on the projected 2029 average. Momentum favours further upside here.
The DGX price prediction for 2031 points to an average of $406.29 (low $313.54, high $562.57) — a potential gain of +96% on today's $207.44. Buyers look set to stay in control over this stretch.
In 2032, DGX is projected to trade between $342.31 and $629.97, averaging $448.59 — a potential gain of +116% from today's $207.44. That is up +10% on the projected 2031 average. Momentum favours further upside here.
Quest Diagnostics Incorporated's 2033 outlook centres on $482.71, within a $364.51 to $686.67 range. That is up +8% on the projected 2032 average. That marks a +133% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, DGX could reach as high as $812.07, with a base case around $564.12 and support toward $421.79 — roughly +172% from $207.44. Momentum favours further upside here.
Expect DGX to range from $500.02 to $982.60 through 2035. The $675.07 average target implies a +225% move from current prices. That is up +20% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The DGX price prediction for 2040 points to an average of $872.27 (low $619.45, high $1,330.53) — a potential gain of +320% on today's $207.44. Momentum favours further upside here.
In 2050, DGX is projected to trade between $1,231.26 and $3,040.38, averaging $1,859.48 — a potential gain of +796% from today's $207.44. That is up +113% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in DGX today (≈ 4.820671 DGX) could be worth
$8,963.92
+$7,963.92 (+796%) by 2050 · US Dollar
Based on the average projected DGX price of $1,859.48 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in DGXwould be worth at today's price.
$1,000 invested in DGX on Jul 10, 2025 (≈ 5.832604 DGX) would be worth
$1,209.92
+$209.92 (+21.0%) today · 1.21× · US Dollar
Based on a DGX entry price of $171.45 vs. today's $207.44.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $215.72 | $961.62 | -3.8% |
| 1 month ago | $203.78 | $1,017.96 | +1.8% |
| 3 months ago | $191.51 | $1,083.18 | +8.3% |
| 6 months ago | $175.94 | $1,179.04 | +17.9% |
| 1 year ago | $171.45 | $1,209.92 | +21.0% |
| All time (5.0y) ago | $135.04 | $1,536.14 | +53.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our DGX forecast.
Our base-case forecast reaches $410.00 around 2032.
Implied market cap at $410.00: $45.39B
The multi-year forecast depicts a rising trajectory after a neutral 2026, with the average price advancing from year to year toward substantially higher levels. Notably, 2030 shows an average of $409.33 with a 95% ROI, 2040 shows an average of $938.62 with a 347.2% ROI, and 2050 shows an average of $1,971.70 with an 839.4% ROI. The model also provides higher max values in later years, such as $558.34 in 2030, $1,432.22 in 2040, and $3,224.66 in 2050, reflecting substantial upside potential alongside clear risk that forecasts are estimates and not guarantees.
The path suggests a bullish sentiment persists through 2031 onward, but outcomes depend on market conditions and other factors beyond the forecast.
Tap a question to reveal the answer.
Avg $409.33; min $319.58; max $558.34; ROI 95%; sentiment BULLISH.
Forecasts show bullish sentiment from 2027 onward with rising averages: 2027 avg $275.09 (ROI 31.1%), 2028 avg $325.77 (ROI 55.2%), 2029 avg $372.52 (ROI 77.5%), 2030 avg $409.33 (ROI 95%). The outlook remains bullish for the long term, but it is not a guarantee.
Yes—the forecast max in 2040 is $1,432.22 and in 2050 is $3,224.66, well above $1,000.
Current price $209.88; market cap $23.23B; rank 545.
RSI 70; sentiment BULLISH; 30-day range $193.20-$228.00; support $186.61; resistance $209.88.
Quest Diagnostics Incorporated Community Discussion
0Share your Quest Diagnostics Incorporated price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.